Blocking intracellular NF-κB/IKK2 and p38 MAPK signaling pathways to find a new generation of anti- inflammatory drugs for RA has been a focus for many groups (Szekanecz and Koch, 2007; Drexler et al., 2008; Clark and Dean, 2012). This evidence concerns the gene NFKB1 and rheumatoid arthritis.